Trial Profile
A Randomized, Double-Blind, Crossover Study in Healthy Volunteers to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers (Vifor SA and Biogen Idec OSD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jun 2015
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 08 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 26 Jun 2014 New trial record